Nanostructured Porous Silicon For Ophthalmic Implants
Funder
National Health and Medical Research Council
Funding Amount
$536,657.00
Summary
Blindness exerts major physical, emotional and economic constraints upon the sufferer. Our goal is to develop novel nanostructured porous silicon-based implants to improve outcomes for patients prone to recurrent episodes of inflammation in the eye, or with visual loss following ocular trauma or infection. Treatments are available, but are not always effective. Porous silicon is a non-toxic, non-inflammatory, biodegradable material that can be loaded with drugs or cells for transfer to the eye.
Engineered Antibody Fragments For The Diagnosis And Treatment Of Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$196,886.00
Summary
We plan to investigate the use of genetically-engineered antibody fragments in the diagnosis and treatment of clinically-important human eye diseases. The work will be carried out in experimental models, but the goal is to develop a new class of drugs that will be widely applicable in human inflammatory eye disease and eye infections. Antibodies are natural proteins, found in blood and body secretions, that protect humans from infections. However, they can be made in the laboratory and monoclona ....We plan to investigate the use of genetically-engineered antibody fragments in the diagnosis and treatment of clinically-important human eye diseases. The work will be carried out in experimental models, but the goal is to develop a new class of drugs that will be widely applicable in human inflammatory eye disease and eye infections. Antibodies are natural proteins, found in blood and body secretions, that protect humans from infections. However, they can be made in the laboratory and monoclonal antibodies in particular - those with a single defined specificity - have found widespread use in many medical applications. For the past 15 years, monoclonal antibodies have been used therapeutically, that is, they have been administered to humans to treat some diseases. Antibodies are big proteins that have multiple functions. Their very size and the multiplicity of their actions prevent their use in some therapeutic situations. In recent years, advances in genetic engineering and biotechnology have developed to the extent that small fragments of monoclonal antibodies can be produced in the laboratory with relative ease. Such fragments should have very substantial advantages over intact antibodies in the diagnosis and treatment of human eye disease. Engineered antibody fragments hold enormous potential for ophthalmic use, especially if they can be administered topically as eye-drops. In this project, we aim to determine whether antibody fragments can be used in the diagnosis and the treatment of four potentially blinding conditions: acute anterior uveitis and corneal graft rejection, which are inflammatory eye diseases, and herpetic keratitis and Acanthamoeba keratitis, which are eye infections.Read moreRead less
Gene Transfer For Corneal Transplantation And Limbal Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$743,463.00
Summary
The cornea is the clear window at the front of the eye. Corneal disease is the second most common reason for blindness in the world. It is sometimes made worse by additional disease affecting the ocular surface. Replacement of a damaged cornea, or of the elements that maintain a normal ocular surface, is possible by transplantation of tissue (either the cornea or the limbus) from a donor eye. The alternative, an artificial cornea, has never yet been reported to function nearly as well as does a ....The cornea is the clear window at the front of the eye. Corneal disease is the second most common reason for blindness in the world. It is sometimes made worse by additional disease affecting the ocular surface. Replacement of a damaged cornea, or of the elements that maintain a normal ocular surface, is possible by transplantation of tissue (either the cornea or the limbus) from a donor eye. The alternative, an artificial cornea, has never yet been reported to function nearly as well as does a successful corneal graft, because the interface between the patient and the prosthesis breaks down and serious problems such as infection are common. Transplantation of the cornea is very successful in some patients but in a sizable subgroup, the graft will fail because of an unwanted immune response. Rejection is the usual cause of a graft failure. Grafts to repair a damaged ocular surface also fail from rejection. Overcoming an unwanted immune response would improve the outcome of corneal transplantation by as much as thirty percent. Overcoming the twin problems of corneal graft rejection and ocular surface disease would make transplantation a feasible option for millions of blind individuals. Novel approaches to abrogation of the immune response to ocular tissue grafts are required, because the many developments in immunosuppression that have improved the survival of other types of transplants have not improved the outcome for grafts in the eye. The immunobiology of the eye is sufficiently different from that of solid organs to demand a different approach. We plan to investigate the use of localised gene transfer to donor eye tissue prior to transplantation, to improve corneal graft and limbal graft outcome.Read moreRead less
Novel Ophthalmic Topical Formulation Targeting Molecular Pathogenesis Of Corneal Haze
Funder
National Health and Medical Research Council
Funding Amount
$296,090.00
Summary
Presently, no drugs are proven to cure corneal haze/scarring, major leading cause of global blindness. Haze is caused by eye trauma, infections or refractive laser surgeries. We aim to test a non toxic, novel ophthalmic topical formulation developed to act on molecular and cellular targets of haze formation. The successful completion of the study will determine formulation’s optimal dose, safety and efficacy for its future potential clinical use in reversing corneal scarring/haze without side ef ....Presently, no drugs are proven to cure corneal haze/scarring, major leading cause of global blindness. Haze is caused by eye trauma, infections or refractive laser surgeries. We aim to test a non toxic, novel ophthalmic topical formulation developed to act on molecular and cellular targets of haze formation. The successful completion of the study will determine formulation’s optimal dose, safety and efficacy for its future potential clinical use in reversing corneal scarring/haze without side effects.Read moreRead less
THE ROLE OF MONOCYTIC LINEAGE CELLS IN MODELS OF CORNEAL DISEASE
Funder
National Health and Medical Research Council
Funding Amount
$311,567.00
Summary
Vision relies on sharp, focused undistorted images passing through the cornea, the clear 'window' at the front of the eye. Corneal disease causes over 5 million cases of blindness worldwide. In patients who damage the delicate covering of the cornea, due to trauma or contact lens wear, there is an increased risk of infection that may lead to blindness. This project will study the ways in which immune cells in the cornea detect invasion by potential pathogens.
Toxoplasma Gondii Infection Of Human Retinal Pigment Epithelium
Funder
National Health and Medical Research Council
Funding Amount
$460,668.00
Summary
Ocular toxoplasmosis is a vision-threatening parasitic eye infection that is common in Australia and worldwide. No treatment cures the disease. This work will characterize cellular and molecular events occuring in the eye during an infection, which is an important first step toward the development of more effective treatments for patients with the condition.
Investigations Into The Aetiology Of Giant Cell Arteritis
Funder
National Health and Medical Research Council
Funding Amount
$165,067.00
Summary
Despite much research the precise pathoetiology of giant cell arteritis is poorly understood. Both environmental and genetic factors are thought to contribute to disease development. Though to date, no overriding mechanism for disease development has been identified. This research will apply modern molecular techniques to further explore the pathogenic processes in this devastating disease which in turn will hopefully provide insight into novel treatment modalities.
Pterygia, one of the most common ocular complaints in Australia and worldwide, are thought to originate from overexposure to UV light. We propose that UV-irradiation stimulate certain cells in the eye to produce cytokines, growth factors and enzymes which degrade scaffold proteins such as collagens. These enzymes may play a key role in the progressive and invasive nature of pterygia. Dissecting the mechanism(s) by which UV light induces these proteins will lead to new and more reliable therapies ....Pterygia, one of the most common ocular complaints in Australia and worldwide, are thought to originate from overexposure to UV light. We propose that UV-irradiation stimulate certain cells in the eye to produce cytokines, growth factors and enzymes which degrade scaffold proteins such as collagens. These enzymes may play a key role in the progressive and invasive nature of pterygia. Dissecting the mechanism(s) by which UV light induces these proteins will lead to new and more reliable therapies for the treatment of pterygia.Read moreRead less
Development Of A Novel Bioengineered Tissue Construct For Repairing The Eye.
Funder
National Health and Medical Research Council
Funding Amount
$335,817.00
Summary
Corneal diseases are often treated using donor tissue transplants. Nevertheless, donor tissue is unsuitable for treating the peripheral or limbal margin of the cornea. We have therefore developed a way to transplant sheets of limbal tissue (epithelium) grown in the laboratory from a patient's own cells, but this tissue lacks a foundation of connective tissue that we believe is essential for sustained healing. Thus, our aim is to develop a novel limbal transplant which contains both layers.